Business
Race Oncology (ASX:RAC) share price slides on a new melanoma preclinical study
The Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new preclinical study by the specialty pharmaceutical company. At the time of writing, shares are down 0.5% to $3.98.
Race Oncology share price unfazed by Bisantrene study
Race Oncology focuses on the development of cancer-targeting drugs in an effort towards better outcomes. The company’s flagship drug is Bisantrene, a small molecule inhibitor of the fat mass and obesity-associated (FTO) protein. A link between FTO and a range of cancers has led Race to investigate Bisantrene further.
According to the release, Race has now entered…
-
General17 hours agoIran expands dog-walking ban, citing ‘public health, peace and comfort’ concerns
-
Noosa News16 hours agoFormer NRL player Teui ‘TC’ Robati lured woman to pub toilet before alleged rape, jury told
-
General16 hours agoUS and Chinese officials meet in the UK for trade talks
-
General23 hours agoBackstroke star Kaylee McKeown disqualified, but wins protest at world champ trials